Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

0.2008
+0.00170.85%
Volume:71.10K
Turnover:14.26K
Market Cap:5.12M
PE:-0.18
High:0.2049
Open:0.2000
Low:0.2000
Close:0.1991
52wk High:1.86
52wk Low:0.1593
Shares:25.48M
Float Shares:24.18M
Volume Ratio:2.04
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0878
EPS(LYR):-1.5837
ROE:-241.14%
ROA:-118.81%
PB:1.69
PE(LYR):-0.13

Loading ...

BioRestorative to present new Phase 2 lumbar disc disease trial data at ISCT 2026

Reuters
·
Apr 30

BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for lumbar disc disease

Reuters
·
Apr 24

BioRestorative Therapies announces partnership with David Goldberg, M.D.

TIPRANKS
·
Apr 21

BioRestorative Therapies Announces Strategic Partnership With Global Dermatology Leader DR. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative Biocosmeceutical Platform

THOMSON REUTERS
·
Apr 21

BioRestorative: Strong Phase 2 BRTX-100 Data and Upcoming 2027 Catalyst Underpin Buy Rating and Attractive Risk‑Reward

TIPRANKS
·
Apr 10

BioRestorative partners with 203 Creates to commercialize biocosmeceutical skincare platform

Reuters
·
Apr 07

BioRestorative Therapies Announces Strategic Collaboration With 203 Creates to Build and Commercialize Biocosmeceutical Platform

THOMSON REUTERS
·
Apr 07

BioRestorative Therapies announces special shareholder meeting on authorized share increase proposal

Reuters
·
Apr 04

BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital

TIPRANKS
·
Apr 02

BRIEF-Biorestorative Therapies Reports Positive Phase 2 Blinded Data For Brtx-100

Reuters
·
Mar 30

BioRestorative Therapies Inc - Reports Phase 2 Data for Brtx-100 With 50%+ Patients Showing >50% Improvement

THOMSON REUTERS
·
Mar 30

BioRestorative Therapies Inc - No Adverse Events Related to Dose-Limiting Toxicities Associated With Hypoxic-Cultured Mesenchymal Stem Cells

THOMSON REUTERS
·
Mar 30

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

GlobeNewswire
·
Mar 30

BioRestorative Therapies Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $19.600K Miss $520.000K Estimate

Benzinga Earnings
·
Mar 27

BioRestorative Therapies Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
Mar 23

BioRestorative Therapies to present Phase 2 blinded BRTX-100 data at Orthopaedic Research Society annual meeting

Reuters
·
Mar 19

BioRestorative Therapies to Participate in Be+Well Beauty and Wellness Show in New York City

Reuters
·
Mar 05

BioRestorative Therapies issues letter to shareholders

TIPRANKS
·
Mar 04

BioRestorative Therapies Inc. Announces Availability of Shareholder Letter

Reuters
·
Mar 04

BioRestorative Completes Phase 2 BRTX-100 Enrollment and Raises $5 Million in Public Offering

Reuters
·
Mar 04